News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN)’s MedImmune (AZN) Presents Encouraging Immunotherapy Data at American Society of Clinical Oncology 2014


6/3/2014 9:49:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO--(BUSINESS WIRE)--MedImmune, the global biologics research and development arm of AstraZeneca, presented results today from its novel investigational immunotherapy portfolio, focusing on MEDI4736, at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. Overall, studies demonstrated durable clinical activity and tolerability for MEDI4736 across a range of tumor types.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES